Treatment of myelodysplastic syndrome and acute myeloid leukemia by immunomodulatory and epigenetic drugs

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F13%3A00010723" target="_blank" >RIV/00023736:_____/13:00010723 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.5772/52099" target="_blank" >http://dx.doi.org/10.5772/52099</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5772/52099" target="_blank" >10.5772/52099</a>

Result language
angličtina
Original language name
Treatment of myelodysplastic syndrome and acute myeloid leukemia by immunomodulatory and epigenetic drugs
Original language description
Acute myeloid leukemia (AML) is associated with poor prognosis in elderly patients. More effective, less toxic therapies for older patients with AML who are not eligible for standard intensive induction therapy or have refractory or relapsed disease after chemotherapy are urgently needed. Epigenetic approaches with hypomethylating agents and histone deacety lase inhibitors and immunomodulatory drugs used in advance in the treatment of patients with myelodysplastic syndrome (MDS) have been also studied in patients with AML [1-15].
Czech name
—
Czech description
—

Project
<a href="/en/project/NT13836" target="_blank" >NT13836: The study of the myelodysplastic syndrome pathogenesis in patients with isolated del(5q) abnormality and the analysis of the effect of lenalidomide</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)